← Back to patent-cliff list
Celecoxib/Ciprofloxacin
Tier C — Watch / tradeCelecoxib/Ciprofloxacin
Neurosense Therapeutics Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：COX-2, Bacterial DNA gyrase, DNA topoisomerase
Brand：PrimeC-ER, CogniC, PrimeC, StabiliC
Indications (approved)：Amyotrophic lateral sclerosis, Alzheimer's disease
Regional status
US
Phase I
2019-12-09
EU
Phase II
2022-05-31
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Celecoxib/Ciprofloxacin?
Approved indications include: Amyotrophic lateral sclerosis, Alzheimer's disease.
When does the Celecoxib/Ciprofloxacin patent expire?
No public expiry year is available for Celecoxib/Ciprofloxacin yet; this page updates once verified.
How do I get a quote for Celecoxib/Ciprofloxacin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05